BOLT News and Press, Bolt Biotherapeutics Inc. From 09/28/23

2023-09-28 08:28:33 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics For further details see: Bolt Bio spikes on FD...

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers The FDA granted BDC-1001 Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal j...

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S...

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: ...

First patients dosed in the BDC-1001 Phase 2 program BDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with nivolumab in HER2-expressing tumors BDC-3042 received IND clearance; clinical trial e...

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers BDC-1001 administered to initial patients in Phase 2 dose-expansion cohorts REDWOOD CITY, Calif., Aug. 03, 2023 ...

REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the BTIG Virtua...

Diagnostear, a subsidiary of BioLight Life Sciences Ltd, signed a binding Letter of Intent for merger, capital raise and listing on the Canadian Securities Exchange PR Newswire TEL AVIV , Israel , June 12, 2023 /PRNewswire/ -- BioLight a publicly traded compa...

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab 20 mg/kg dosed every other week (q2w) was selected as the RP2D BDC-1001 advancing...

2023-05-11 17:02:28 ET Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q1 GAAP EPS of -$0.45. Revenue of $1.83M (+125.9% Y/Y). For further details see: Bolt Biotherapeutics GAAP EPS of -$0.45, revenue of $1.83M